产品
编 号：F291737
分子式：C11H22N6O4
分子量：302.33
分子式：C11H22N6O4
分子量：302.33
产品类型
规格
价格
是否有货
结构图
CAS No: 2483-17-2
产品详情
生物活性：
Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy.
体内研究：
Arginyl-Glutamine (1-5 g/kg/day as a hydrochloride salt; i.p.; twice daily) 显著抑制小鼠氧诱导视网膜病变 (OIR) 模型中的视网膜新生血管。Animal Model:C57BL6/J mouse pups, oxygen-induced retinopathy (OIR) model
Dosage:1.0, 2.5, or 5 g/kg per day
Administration:Intraperitoneal injection, twice daily
Result:Significantly decreased preretinal nuclei. Reduced neovascular tufts and vascular leakage in retinal vessels. Reduced preretinal neovascularization by 82% ± 7% and reduced VEGF mRNA by 64% ± 9% at 5 g/kg per day.
体外研究：
Arginyl-Glutamine (0.5-1.5 mM; 48 h) 会导致人类 RPE 细胞中可溶性 VEGF 在培养基中的表达呈统计学意义上的剂量依赖性下降。
Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy.
体内研究：
Arginyl-Glutamine (1-5 g/kg/day as a hydrochloride salt; i.p.; twice daily) 显著抑制小鼠氧诱导视网膜病变 (OIR) 模型中的视网膜新生血管。Animal Model:C57BL6/J mouse pups, oxygen-induced retinopathy (OIR) model
Dosage:1.0, 2.5, or 5 g/kg per day
Administration:Intraperitoneal injection, twice daily
Result:Significantly decreased preretinal nuclei. Reduced neovascular tufts and vascular leakage in retinal vessels. Reduced preretinal neovascularization by 82% ± 7% and reduced VEGF mRNA by 64% ± 9% at 5 g/kg per day.
体外研究：
Arginyl-Glutamine (0.5-1.5 mM; 48 h) 会导致人类 RPE 细胞中可溶性 VEGF 在培养基中的表达呈统计学意义上的剂量依赖性下降。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备